Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-24

Clinical Trial Update: Oxytocin as Adjunctive Therapy for Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oxytocin as adjunctive therapy for schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxytocin (Oxytocin)

Snippet

Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED